Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | GSK3B | P49841 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.40 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.40 |
| ▸ | MGLL | Q99685 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | BCL9 | O00512 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8932106 | 0.85 | CA2 (0.52) | MEN1KMT2ALMNAALDH1A1CA2 | |
| SCHEMBL4930510 | 0.83 | MMP1 (0.46) | MEN1KMT2ALMNAALDH1A1CA2 | |
| SCHEMBL4930519 | 0.83 | MMP1 (0.46) | MEN1KMT2ALMNAALDH1A1CA2 | |
| SCHEMBL3572564 | 0.80 | CA2 (0.49) | MEN1KMT2ALMNAGSK3BCA2 | |
| SCHEMBL14374796 | 0.79 | KMT2A (0.46) | MEN1KMT2ALMNAALDH1A1CA2 | |
| SCHEMBL468113 | 0.78 | PPARG (0.56) | MEN1KMT2ALMNACA2ITGA4 | |
| SCHEMBL8932129 | 0.78 | MEN1 (0.40) | MEN1KMT2ALMNAALDH1A1CA2 | |
| SCHEMBL17083262 | 0.78 | PPARG (0.56) | MEN1KMT2ALMNACA2ITGA4 | |
| SCHEMBL500869 | 0.78 | PPARG (0.56) | MEN1KMT2ALMNACA2ITGA4 | |
| SCHEMBL8021733 | 0.78 | MEN1 (0.47) | MEN1KMT2ALMNAALDH1A1MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8338615-B2 | Human protein tyrosine phosphatase inhibitors and methods of use | AERPIO THERAPEUTICS INC. (US) | 2012-12-25 | — | — | US | disclosed |
| US-8188125-B2 | Human protein tyrosine phosphatase inhibitors and methods of use | AERPIO THERAPEUTICS INC. (US) | 2012-05-29 | — | — | US | disclosed |
| US-20120077853-A1 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE | EyePoint Pharmaceuticals, Inc. | 2012-03-29 | — | — | US | disclosed |
| US-7589212-B2 | {4-[2-(5-methyl-[1,3,4]thiadiazol-2-ylamino)-2-(4-phenylthiazol-2-yl)-ethyl]phenyl}sulfamic acid; anticarcinogenic, antitumor, antidiabrtic agent; angiogenesis inhibitor; sarcoid, syphilis, Paget's disease, vein occlusion, artery occlusion, carotid obstructive disease, chronic uveitis/vitritis | PROCTER & GAMBLE COMPANY (US) | 2009-09-15 | — | — | US | disclosed |
| US-20090227639-A1 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE | EyePoint Pharmaceuticals, Inc. | 2009-09-10 | — | — | US | disclosed |
| US-20070299116-A1 | {4-[2-(5-methyl-[1,3,4]thiadiazol-2-ylamino)-2-(4-phenylthiazol-2-yl)-ethyl]phenyl}sulfamic acid; anticarcinogenic, antitumor, antidiabrtic agent; angiogenesis inhibitor; sarcoid, syphilis, Paget's disease, vein occlusion, artery occlusion, carotid obstructive disease, chronic uveitis/vitritis | THE PROCTER & GAMBLE COMPANY (US) | 2007-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070299116-A1 | {4-[2-(5-methyl-[1,3,4]thiadiazol-2-ylamino)-2-(4-phenylthiazol-2-yl)-ethyl]phenyl}sulfamic acid; anticarcinogenic, antitumor, antidiabrtic agent; angiogenesis inhibitor; sarcoid, syphilis, Paget's disease, vein occlusion, artery occlusion, carotid obstructive disease, chronic uveitis/vitritis | DUSP15, PPP5C, DUSP1 | MEN1 4526/4885KMT2A 3966/4885LMNA 4409/4885 |
| US-20120077853-A1 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE | PTPRCAP, PPP5C, PTPRC | MEN1 3705/4885KMT2A 3601/4885LMNA 4555/4885 |
| US-20090227639-A1 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE | PTPRCAP, PPP5C, PTPRC | MEN1 3705/4885KMT2A 3601/4885LMNA 4555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.